Related references
Note: Only part of the references are listed.Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity
Alexandra E. Stacy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents
Li-Ying Ma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Molecular mechanisms of epithelial-mesenchymal transition
Samy Lamouille et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Berberine Reverses Epithelial-to-Mesenchymal Transition and Inhibits Metastasis and Tumor-Induced Angiogenesis in Human Cervical Cancer Cells
Shu-Chen Chu et al.
MOLECULAR PHARMACOLOGY (2014)
In Vitro and in Vivo Anticancer Activity of Copper Bis(thiosemicarbazone) Complexes
Duraippandi Palanimuthu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy
Y. Yu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Iron Chelators for the Treatment of Cancer
Y. Yu et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo
David B. Lovejoy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes
David B. Lovejoy et al.
CANCER RESEARCH (2011)
The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer
Zaklina Kovacevic et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Role of Metalation in the Topoisomerase Ilα Inhibition and Antiproliferation Activity of a Series of α-Heterocyclic-N4-Substituted Thiosemicarbazones and Their Cu(II) Complexes
Brian M. Zeglis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer
Zaklina Kovacevic et al.
MOLECULAR PHARMACOLOGY (2011)
Fluorescence properties and cellular distribution of the investigational anticancer drug Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex
Christian R. Kowol et al.
DALTON TRANSACTIONS (2010)
A phase II trial of TriapineA® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
Anne M. Traynor et al.
INVESTIGATIONAL NEW DRUGS (2010)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity
Des R. Richardson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors
Yu Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Cellular confocal fluorescence studies and cytotoxic activity of new Zn(II) bis(thiosemicarbazonato) complexes
Sofia I. Pascu et al.
DALTON TRANSACTIONS (2008)
A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine((R))) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders
Judith E. Karp et al.
LEUKEMIA RESEARCH (2008)
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
Brigette Ma et al.
INVESTIGATIONAL NEW DRUGS (2008)
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium
M. J. Mackenzie et al.
INVESTIGATIONAL NEW DRUGS (2007)
Pre-EMTing metastasis?: Recapitulation of morphogenetic processes in cancer
Geert Berx et al.
CLINICAL & EXPERIMENTAL METASTASIS (2007)
Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones
Christian R. Kowol et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2007)
Phase II study of triapinea® in patients with metastatic renal cell carcinoma:: A trial of the national cancer institute of canada clinical trials group (NCIC IND.161)
Jennifer J. Knox et al.
INVESTIGATIONAL NEW DRUGS (2007)
Gallium(III) and Iron(III) complexes of α-N-heterocyclic thiosemicarbazones:: Synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase
Christian R. Kowol et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Chelators at the cancer coalface: Desferrioxamine to triapine and beyond
Yu Yu et al.
CLINICAL CANCER RESEARCH (2006)
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity
Des R. Richardson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Complex networks orchestrate epithelial-mesenchymal transitions
JP Thiery et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Fluorescence studies of the intra-cellular distribution of zinc bis(thiosemicarbazone) complexes in human cancer cells
AR Cowley et al.
CHEMICAL COMMUNICATIONS (2005)
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment
J Yuan et al.
BLOOD (2004)
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer
Y Yen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Expression profiling of epithelial plasticity in tumor progression
M Jechlinger et al.
ONCOGENE (2003)
The role of iron chelation in cancer therapy
JL Buss et al.
CURRENT MEDICINAL CHEMISTRY (2003)
Novel hybrid iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells
DB Lovejoy et al.
BLOOD (2002)
Triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
RA Finch et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
